MARKER THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.22 USD | +1.20% |
|
-0.24% | -23.27% |
| May. 15 | Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M | MT |
| Apr. 30 | Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target | MT |
Presenter SpeechAnthony Kim (Executives)Good morning and welcome to the Marker Therapeutics Co...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.17
USD
Average target price
11
USD
Spread / Average Target
+163.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.27% | 37.17M | |
| +31.12% | 49.46B | |
| +1.16% | 42.58B | |
| +49.00% | 42.49B | |
| -5.26% | 29.09B | |
| +12.78% | 26.61B | |
| -23.69% | 18.64B | |
| +7.32% | 13.16B | |
| +31.42% | 12.55B | |
| +23.60% | 12.1B |
- Stock Market
- Equities
- MRKR Stock
- News Marker Therapeutics, Inc.
- Transcript : Marker Therapeutics, Inc. - Special Call
